| 1 |
Yu Y, Cai J, She Z, Li H．Insights into the epidemiology，pathogenesis，and therapeutics of nonalcoholic fatty liver diseases[J]．Adv Sci，2019，6(4):180-185.
|
| 2 |
Rinella ME.Nonalcoholic fatty liver disease：a systematic review[J]．JAMA，2015，313(22):2263-2273.
|
| 3 |
Diehl AM, Day C．Cause，pathogenesis，and treatment of nonalcoholic steatohepatitis[J]．N Engl J Med，2017，377(21):2063-2072.
|
| 4 |
曾民德．非酒精性脂肪性肝病：回顾历史，展望未来[J]．实用肝脏病杂志，2016，19(3):129-131.
|
| 5 |
Byrne CD, Patel J, Scorletti E, Targher G．Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults[J]．BMJ，2018，362:k2734.
|
| 6 |
Doycheva I, Cui J, Nguyen P，et al.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE[J]．Aliment Pharmacol Ther, 2016，43(1):83-95.
|
| 7 |
McPherson S, Stewart SF, Henderson E，et al.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]．Gut，2010，59(9):1265-1269.
|
| 8 |
Machado MV, Cortez-Pinto H．Non-invasive diagnosis of non-alcoholic fatty liver disease.A critical appraisal[J]．J Hepatol，2013，58(5):1007-1019.
|
| 9 |
Loomba R．Role of imaging-based biomarkers in NAFLD：Recent advances in clinical application and future research directions[J]．J Hepatol，2018，68(2):296-304.
|
| 10 |
McPherson S, Henderson E, Burt AD，et al.Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease[J]．J Hepatol，2014，60(5):1055-1062.
|
| 11 |
Liver EAftSot, Diabetes EAftSo.EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]．Obesity Facts，2016，9(2):65-90.
|
| 12 |
Chalasani N, Younossi Z, Lavine JE，et al.The diagnosis and management of non-alcoholic fatty liver disease：Practice Guideline by the American Association for the Study of Liver Diseases，American College of Gastroenterology，and the American Gastroenterological Association[J]．Hepatol，2012，55(6):2005-2023.
|
| 13 |
McPherson S, Hardy T, Henderson E，et al.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies：implications for prognosis and clinical management[J]．J Hepatol，2015，62(5):1148-1155.
|
| 14 |
沈峰．细胞角蛋白-18联合受控衰减参数二步法无创鉴别非酒精性脂肪性肝炎的临床研究[J]．中华肝脏病杂志，2016，24(6):429-434.
|
| 15 |
Committee FLE, Association CMD.非酒精性脂肪性肝病防治指南(2018年更新版)[J]．实用肝脏病杂志，2018，21(2):177-186.
|
| 16 |
Ratziu V, Goodman Z, Sanyal A．Current efforts and trends in the treatment of NASH[J]．J Hepatol，2015;62(1):S65-S75.
|
| 17 |
Rinella ME, Sanyal AJ.Management of NAFLD：a stage-based approach[J]．Nat Rev Gastroenterol Hepatol，2016，13(4):196.
|
| 18 |
Romero-Gómez M, Zelber-Sagi S, Trenell M．Treatment of NAFLD with diet，physical activity and exercise[J]．J Hepatol，2017，67(4):829-846.
|
| 19 |
York LW, Puthalapattu S, Wu GY.Nonalcoholic fatty liver disease and low-carbohydrate diets[J]．Ann Rev Nutrit，2009，29:365-379.
|
| 20 |
Rodriguez B, Torres DM, Harrison SA.Physical activity：an essential component of lifestyle modification in NAFLD[J]．Nat Rev Gastroenterol Hepatol，2012，9(12):726.
|
| 21 |
Scorletti E, Byrne CD.Omega-3 fatty acids，hepatic lipid metabolism，and nonalcoholic fatty liver disease[J]．Ann Rev Nutrit，2013，33:231-48.
|
| 22 |
Reinehr T．Lifestyle intervention in childhood obesity：changes and challenges[J]．Nat Rev Endocrinol，2013，9(10):607.
|
| 23 |
Thoma C, Day CP, Trenell MI.Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults：a systematic review[J]．J Hepatol，2012，56(1):255-266.
|
| 24 |
Houghton D, Stewart CJ, Day CP, Trenell M．Gut microbiota and lifestyle interventions in NAFLD[J]．Int J Mol Sci，2016，17(4):447.
|
| 25 |
Musso G, Gambino R, Cassader M．Emerging molecular targets for the treatment of nonalcoholic fatty liver disease[J]．Ann Rev Med，2010，61:375-392.
|
| 26 |
Kheong CW, Mustapha NRN, Mahadeva S．A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J]．Clin Gastroenterol Hepatol，2017，15(12):1940-1949.e8.
|
| 27 |
Lassailly G, Caiazzo R, Buob D，et al.Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients[J]．Gastroenterology，2015，149(2):379-388.
|
| 28 |
Merola J, Liapakis A, Mulligan DC，et al.Non-alcoholic fatty liver disease following liver transplantation：a clinical review[J]．Clin Transplant，2015，29(9):728-737.
|
| 29 |
Wong RJ, Aguilar M, Cheung R，et al.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J]．Gastroenterology，2015，148(3):547-555.
|
| 30 |
Goldberg D, Ditah IC, Saeian K，et al.Changes in the prevalence of hepatitis C virus infection，nonalcoholic steatohepatitis，and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation[J]．Gastroenterology，2017，152(5):1090-1099.e1.
|